Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexios Matikas

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Nature Communications|May 7, 2024
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancerKang Wang, Ioannis Zerdes, Henrik J Johansson, et al.
International Journal of Cancer|December 27, 2024
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancerMaria Kouvaraki, Ioannis Zerdes, Emmanouil G Sifakis, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
Cancer Treatment Reviews|December 12, 2025
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysisAlicia Escudero, Meritxell Bellet, Cristina Saura, et al.
Nature Communications|April 8, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trialAlexios Matikas, Evangelos Tzoras, Michail Sarafidis, et al.
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2025
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> StatusMatteo Lambertini, Eva Blondeaux, Loredana M Tomasello, et al.
Cancer|May 16, 2024
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort studyFrancesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Nature Communications|May 7, 2024
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancerKang Wang, Ioannis Zerdes, Henrik J Johansson, et al.
International Journal of Cancer|December 27, 2024
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancerMaria Kouvaraki, Ioannis Zerdes, Emmanouil G Sifakis, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
Cancer Treatment Reviews|December 12, 2025
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysisAlicia Escudero, Meritxell Bellet, Cristina Saura, et al.
Nature Communications|April 8, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trialAlexios Matikas, Evangelos Tzoras, Michail Sarafidis, et al.
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2025
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> StatusMatteo Lambertini, Eva Blondeaux, Loredana M Tomasello, et al.
Cancer|May 16, 2024
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort studyFrancesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Pageof 10